STAT Plus: Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA
Some of biotech’s most buzzed-about acquisition targets have already been crossed off the “deal imminent” list.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario